PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)

Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02831504

Acronym

PhenoDM1

Enrollment

213

Registered

2016-07-13

Start date

2015-08-31

Completion date

2018-10-31

Last updated

2021-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic Dystrophy Type 1

Keywords

Myotonic Dystrophy type 1, DM1, Muscular Dystrophy, Neuromuscular Diseases

Brief summary

PhenoDM1 will use patient reported outcomes to assess levels of pain, fatigue and quality of life in this cohort. Clinical and functional outcomes will look at muscle wasting and levels of myotonia. DNA, RNA, serum and CSF samples will be taken from all patients so that additional genetic and molecular biomarker analysis can be carried out. A subset of patients will undergo detailed sleep studies along with skeletal muscle MRI of the lower limbs. This study will complement the work of other groups currently looking at myotonic dystrophy type 1 using the same outcomes and measures where possible.

Detailed description

Myotonic Dystrophy type I (DM1) is the most common form of adult muscular dystrophy, affecting 1 in 8000 individuals. It is an autosomal dominant disorder with multisystemic involvement of multiple organs and tissues, namely brain, heart, endocrine system, eyes and both smooth and skeletal muscles. It results from the CTG expansion of an untranslated region 3' terminal of the DMPK gene which causes a disturbance of the RNA metabolism, in particular defective splicing of various pre-mRNAs such as the muscular chloride channel (causing myotonia), the insulin receptor (causing diabetes) and others. We will carry out an in-depth characterisation of 400 adult DM1 patients identified from local clinical populations across England and through the national DM Registry. Over a two year period we will take measurements 12 months apart to address specific symptoms that cause major quality of life impairment including muscle weakness, myotonia, excessive daytime sleepiness and cognitive impairment. DNA samples will be collected in order to determine the CTG repeat length and serum samples for biomarker identification. We will carry out muscle MRI and sleep studies in a subset of 50 patients. The implemented measures will capitalise on the efforts of previous cohort studies ensuring that all measures are comparable with existing datasets.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Main Inclusion Criteria 1. 18 years of age or over 2. Genetic confirmation of Myotonic Dystrophy Type 1 3. Able to consent and willing to participate throughout the duration of the study. Additional Inclusion Criteria for MRI study: 1. Aged between 18 and 55 years 2. Ambulant or ambulant-assisted Additional Inclusion Criteria for sleep study: 1\. Aged between 18 and 55 years

Exclusion criteria

Main

Design outcomes

Primary

Measure	Time frame	Description
Strength and function	9-12 months	These assessments include: * Manual Muscle Testing * Quantitative Muscle Testing (Hand Held Myometry, Hand-Grip Dynamometry) * Pulmonary function testing (FVC and MIP) * Functional evaluations (Nine Hole Peg Test, Six Minute Walk Test, 30 Seconds Sit and Stand Test, Timed 10-Meter Walk Test, Scale for Assessment and Rating of Ataxia Scale, Accelerometry Assessment)

Secondary

Measure	Time frame	Description
Cognitive assessment	9-12 months	These questionnaires include: * Mini-Mental State Examination (MMS) * Trail Making Test (TMT) * Apathy Evaluation Scale (AES)
Quality of Life using patient-reported outcomes	9-12 months	These questionnaires include: * Individualised Neuromuscular Quality Of Life (InQoL) * Myotonic Dystrophy Health Index (MDHI)
Fatigue and Daytime Sleepiness assessment using patient-reported outcomes	9-12 months	These questionnaires include: * Checklist Individual Strength * Epworth Sleepiness Scale * Fatigue and Daytime Sleepiness Scale
Blood and Urine collection for genetic and molecular biomarker analysis	9-12 months	Collection of: RNA, DNA, Serum and Urine
Blood collection for Glycated Haemoglobin (HbA1c), Thyroid hormones, Androgens (in males only) analysis	9-12 months	—
Pain assessment using patient-reported outcomes	9-12 months	These questionnaires include: * McGill questionnaire * IVR Scale

Other

Measure	Time frame	Description
Sleep Study	9-12 months	Assessment by polysomnography and maintenance of wakefulness test (MWT)
Skeletal Muscle MRI of the lower extremities	9-12 months	Three imaging scans will be acquired of the lower extremities: T1-weighted images, TIRM images and Dixon images.

Countries

United Kingdom

Outcome results